SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

29 May 2023 Evaluate
The revenue for the March 2023 quarter is pegged at Rs. 1730.36 millions, about 6.69% up against Rs. 1621.93 millions recorded during the year-ago period.The Net Profit of the company registered a slight decline of -10.66% to Rs. 181.05  millions from Rs. 202.65 millions.OP of the company witnessed a marginal growth to 327.72 millions from 327.08 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 1730.36 1621.93 6.69 6906.21 7791.56 -11.36 6906.21 7791.56 -11.36
Other Income 6.23 0.41 1419.51 25.74 31.04 -17.07 25.74 31.04 -17.07
PBIDT 327.72 327.08 0.20 1372.25 1511.34 -9.20 1372.25 1511.34 -9.20
Interest 29.22 13.06 123.74 82.23 53.66 53.24 82.23 53.66 53.24
PBDT 298.50 314.02 -4.94 1290.02 1457.68 -11.50 1290.02 1457.68 -11.50
Depreciation 59.18 52.25 13.26 222.81 189.29 17.71 222.81 189.29 17.71
PBT 239.32 261.77 -8.58 1067.21 1268.39 -15.86 1067.21 1268.39 -15.86
TAX 58.27 59.12 -1.44 270.16 309.98 -12.85 270.16 309.98 -12.85
Deferred Tax -3.73 -7.38 -49.46 -11.94 -11.52 3.65 -11.94 -11.52 3.65
PAT 181.05 202.65 -10.66 797.05 958.41 -16.84 797.05 958.41 -16.84
Equity 96.94 96.94 0.00 96.94 96.94 0.00 96.94 96.94 0.00
PBIDTM(%) 18.94 20.17 -6.08 19.87 19.40 2.44 19.87 19.40 2.44

Gufic Biosciences Share Price

301.30 -1.35 (-0.45%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×